Universität zu Köln

Kron, Anna, Quaas, Alexander and Zander, Thomas (2017). Treatment reality of the molecular diagnostics of malignant diseases. Onkologe, 23 (11). S. 900 - 911. NEW YORK: SPRINGER. ISSN 1433-0415

Full text not available from this repository.

Abstract

Background. In recent years oncogene driver mutations and predictors for targeted immunotherapy were detected for various types of cancer. Sound therapy decision making increasingly requires complex molecular diagnostics; nevertheless, there is still a lack of a broad implementation of comprehensive genomic testing in Germany. Goal. Presentation of the treatment reality of molecular cancer diagnostics with the focus on the relevance of multiplex testing, quality of testing and financing. Methods. This article is based on a selective literature research in the PubMed database and own empirical reports using the example of the Network Genomic Medicine, including a summary of the currently valid legal situation and guidelines for the reimbursement of molecular diagnostics. Results. The key role of a comprehensive quality assured multiplex diagnostics for the optimal treatment selection is presented based on the example of lung cancer, the most common cause of cancer deaths in Germany. Due to the dynamic development of targeted therapies based on the results of primary and recurrent testing, molecular diagnostics must be accessible to all affected patients in Germany. Discussion. In order to ensure the outcome validity for each patient, consistently high-quality criteria must be implemented. Current lack of reimbursement (especially during inpatient treatment) have a negative impact on the nationwide test rates. The German billing system remains relatively inflexible in dealing with medical innovations. The future of personalized cancer therapies lies in the interdisciplinary and intersectoral medical networks.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kron, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Quaas, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Zander, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-212610
DOI:	10.1007/s00761-017-0283-x
Journal or Publication Title:	Onkologe
Volume:	23
Number:	11
Page Range:	S. 900 - 911
Date:	2017
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1433-0415
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL LUNG-CANCER; OPEN-LABEL; MEK INHIBITION; BREAST-CANCER; PHASE-3 TRIAL; COMBINED BRAF; CHEMOTHERAPY; CRIZOTINIB; MELANOMA; MUTATIONS Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/21261